Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Pipeline Assessment | Insights into the Current Therapies, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook

August 17 18:33 2022
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Pipeline Assessment | Insights into the Current Therapies, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, nearly 300+ key pharma and biotech companies are working on 300+ pipeline drugs in the CAR-T therapeutics landscape based on different routes of administration (RoA), Mechanism of Action (MoA) and molecule types. Several of the therapies are in the advanced stages of clinical development expected to launch in the coming years.

Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Pipeline Insight, 2022” report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Market. 

The Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

“Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Pipeline” report covers around 300+ products under different phases of clinical development like – 

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about companies that are developing Chimeric Antigen Receptor T-Cell Therapy (CAR-T).
  • It accesses the different CAR-T therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development.
  • Chimeric Antigen Receptor T-Cell Therapy (CAR-T) key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Chimeric Antigen Receptor T-Cell Therapy (CAR-T) that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Chimeric Antigen Receptor T-Cell Therapy (CAR-T) market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Request for Sample PDF Report – https://www.delveinsight.com/sample-request/chimeric-antigen-receptor-t-cell-therapy-car-t-pipeline-insight

Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Therapeutics Landscape

As per DelveInsight, there are approx. 300+ key companies which are developing the therapies for CAR-T. Currently, JW therapeutics has its CAR-T drug candidates in the most advanced stage of clinical development.

 

Chimeric Antigen Receptor T-Cell Therapy (CAR-T) – Emerging Drugs

• CAR-GPC3

• CAR-TaNK cell therapy

• Descartes-08

• TT11

• CYAD-203

• GPC2 CAR-T

• BPX-601

• AUTO4

• CT 103A

• JWCAR029

• CEA CAR T

• Descartes-11

• CNCT19

• CTL119

• KTE-X19

• CART-19/22

And many more

 

Some of the key companies in the Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Market include:

• JW Therapeutics

• Sorrento Therapeutics

• Cartesian Therapeutics

• CASI Pharmaceuticals

• Juventas Cell Therapy

• Novartis

• Gilead Sciences

• Shanghai Unicar-Therapy Bio-medicine Technology

• Carsgen Therapeutics

• EXUMA BIOTECHNOLOGY

• Cartesian Therapeutics

• Tessa Therapeutics

• Celyad Oncology

• Tmunity Therapeutics

• Bellicum Pharmaceuticals

• Autolus Limited

• IASO Biotherapeutics

And several others

Get More Detailed Insights Into the Emerging Therapies & Key Companies –  https://www.delveinsight.com/sample-request/chimeric-antigen-receptor-t-cell-therapy-car-t-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Current Treatment Patterns

4. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Late Stage Products (Phase-III)

7. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Mid-Stage Products (Phase-II)

8. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Discontinued Products

13. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Product Profiles

14. Key Companies in the Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Market

15. Key Products in the Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Therapeutics Segment

16. Dormant and Discontinued Products

17. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Unmet Needs

18. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Future Perspectives

19. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report – https://www.delveinsight.com/sample-request/chimeric-antigen-receptor-t-cell-therapy-car-t-pipeline-insight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

 

Other Trending Healthcare Report by DelveInsight

Methicillin-resistant Staphylococcus Aureus (MRSA) Market
“Methicillin-resistant Staphylococcus Aureus (MRSA) Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Methicillin-resistant Staphylococcus Aureus Market size, share, and trends in the 7MM. Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the MRSA therapeutics Market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

  Categories: